EagleClaw Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

EagleClaw Capital Management’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.77M	Sell	5,629 -605	-10%	-$328K	0.39%	65
2025 Q4	$3.61M	Sell	6,234 -25	-0.4%	-$14.1K	0.52%	53
2025 Q3	$3.04M	Buy	6,259 +45	+0.7%	+$20.9K	0.42%	59
2025 Q2	$2.52M	Sell	6,214 -5	-0.1%	-$2.09K	0.38%	69
2025 Q1	$3.09M	Sell	6,219 -65	-1%	-$35.2K	0.49%	57
2024 Q4	$3.27M	Hold	6,284	–	–	0.52%	54
2024 Q3	$3.89M	Sell	6,284 -75	-1%	-$44.4K	0.65%	48
2024 Q2	$3.52M	Sell	6,359 -95	-1%	-$54.4K	0.63%	46
2024 Q1	$3.75M	Sell	6,454 -150	-2%	-$84.2K	0.68%	48
2023 Q4	$3.51M	Sell	6,604 -50	-0.8%	-$24.2K	0.73%	47
2023 Q3	$3.37M	Sell	6,654 -150	-2%	-$79.9K	0.76%	46
2023 Q2	$3.55M	Sell	6,804 -175	-3%	-$94.4K	0.82%	46
2023 Q1	$4.02M	Sell	6,979 -105	-1%	-$59.2K	0.95%	40
2022 Q4	$3.9M	Sell	7,084 -100	-1%	-$53K	0.94%	40
2022 Q3	$3.64M	Sell	7,184 -75	-1%	-$42K	1.02%	33
2022 Q2	$3.94M	Sell	7,259 -476	-6%	-$262K	1.07%	30
2022 Q1	$4.57M	Sell	7,735 -250	-3%	-$144K	1.05%	31
2021 Q4	$5.33M	Sell	7,985 -125	-2%	-$78K	1.17%	26
2021 Q3	$4.63M	Buy	8,110 +870	+12%	+$478K	1.19%	27
2021 Q2	$3.65M	Sell	7,240 -73	-1%	-$34.4K	0.94%	34
2021 Q1	$3.34M	Sell	7,313 -37	-0.5%	-$17.7K	0.96%	33
2020 Q4	$3.42M	Hold	7,350	–	–	1.09%	28
2020 Q3	$3.25M	Sell	7,350 -100	-1%	-$41.3K	1.14%	27
2020 Q2	$2.7M	Sell	7,450 -300	-4%	-$101K	1.05%	28
2020 Q1	$2.2M	Sell	7,750 -50	-0.6%	-$15.8K	1.04%	34
2019 Q4	$2.53M	Hold	7,800	–	–	0.93%	39
2019 Q3	$2.27M	Sell	7,800 -150	-2%	-$43K	0.93%	33
2019 Q2	$2.33M	Sell	7,950 -200	-2%	-$55.1K	1.01%	29
2019 Q1	$2.23M	Sell	8,150 -250	-3%	-$62.2K	1.02%	29
2018 Q4	$1.88M	Sell	8,400 -100	-1%	-$23.5K	0.99%	30
2018 Q3	$2.07M	Sell	8,500 -100	-1%	-$23K	0.91%	33
2018 Q2	$1.78M	Sell	8,600 -100	-1%	-$21.2K	0.86%	37
2018 Q1	$1.8M	Sell	8,700 -250	-3%	-$52.5K	0.91%	37
2017 Q4	$1.7M	Sell	8,950 -75	-0.8%	-$14.4K	0.86%	45
2017 Q3	$1.71M	Sell	9,025 -175	-2%	-$31.7K	0.97%	39
2017 Q2	$1.6M	Hold	9,200	–	–	0.94%	41
2017 Q1	$1.41M	Sell	9,200 -350	-4%	-$53.5K	0.85%	46
2016 Q4	$1.35M	Sell	9,550 -100	-1%	-$14.7K	0.85%	46
2016 Q3	$1.54M	Buy	9,650 +150	+2%	+$23.1K	0.98%	39
2016 Q2	$1.41M	Sell	9,500 -100	-1%	-$14.8K	0.93%	42
2016 Q1	$1.36M	Sell	9,600 -400	-4%	-$53.6K	0.92%	40
2015 Q4	$1.42M	Hold	10,000	–	–	0.94%	39
2015 Q3	$1.22M	Buy	10,000 +425	+4%	+$55.4K	0.86%	43
2015 Q2	$1.24M	Buy	9,575 +1,925	+25%	+$251K	0.8%	46
2015 Q1	$1.03M	Sell	7,650 -100	-1%	-$12.9K	0.67%	51
2014 Q4	$972K	Hold	7,750	–	–	0.64%	54
2014 Q3	$945K	Sell	7,750 -50	-0.6%	-$6.08K	0.64%	54
2014 Q2	$921K	Sell	7,800 -50	-0.6%	-$5.88K	0.62%	54
2014 Q1	$942K	Buy	+7,850	New	+$933K	0.68%	51

Other funds holding TMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EagleClaw Capital Management's TMO Position: Q1 2026 in Review

EagleClaw Capital Management reduced its Thermo Fisher Scientific (TMO) stake by 9.7% in Q1 2026, selling an estimated $328K and leaving 5,629 shares worth $2.77M. The position accounts for 0.39% of the portfolio, ranked #65.

EagleClaw Capital Management first reported a position in TMO in Q1 2014 and has held it in 49 quarters since. The position peaked at $5.33M in Q4 2021. 2,590 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

EagleClaw Capital Management held 5,629 shares of Thermo Fisher Scientific worth $2.77M as of Q1 2026.
EagleClaw Capital Management sold 605 Thermo Fisher Scientific shares in Q1 2026, an estimated $328K.
Thermo Fisher Scientific made up 0.39% of EagleClaw Capital Management's portfolio in Q1 2026, its #65 holding.
EagleClaw Capital Management first reported a position in Thermo Fisher Scientific in Q1 2014 and has held it in 49 quarters since.
EagleClaw Capital Management's Thermo Fisher Scientific position peaked at $5.33M in Q4 2021.
2,590 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on EagleClaw Capital Management's 13F filing for Q1 2026, filed 8 May 2026.